Emestedastat治疗重性抑郁障碍伴认知损害的2期随机双盲安慰剂对照试验
XanaCIDD试验纳入165例持续抑郁且认知损害的重性抑郁障碍患者,随机接受emestedastat 10 mg或安慰剂治疗6周并盲法随访至第10周。主要认知终点在第6周无获益(p=0.17偏安慰剂),两组认知复合评分均显著改善且与抑郁症状变化不相关;预设次要抑郁终点MADRS在第10周出现最大趋势获益(2.7分,Cohen's d 0.43,p=0.05)。emestedastat组10%出现轻度至中度转氨酶升高,安慰剂组为1%。
要点
- 主要认知终点第6周无获益,p=0.17偏安慰剂,两组认知均显著改善。
- MADRS在第10周最大趋势获益2.7分(Cohen's d 0.43,p=0.05),提示潜在抗抑郁活性。
- emestedastat组10%出现轻度至中度转氨酶升高,安慰剂组1%。
核心结论
- Emestedastat 10 mg对主要认知终点无获益,且安慰剂效应大,认知改善与抑郁变化或基线特征不相关。
- MADRS在第10周出现最大趋势获益,提示emestedastat可能是一种值得进一步研究的新型抗抑郁药。
研究设计与样本
- 2期随机双盲安慰剂对照试验(XanaCIDD),随机比例1:1,治疗6周,盲法随访至第10周。
- 纳入165例重性抑郁障碍患者,要求持续抑郁(HAMD-17≥17)且认知损害(编码测试≤正常0.5个标准差)。
- 134例(81%)正在使用背景抗抑郁药,62%为女性,既往MDD发作平均10次,编码z评分均值-1.47。
主要发现
- 主要认知终点(注意/工作记忆复合评分)第6周无获益,p=0.17偏安慰剂,两组认知复合评分均显著改善。
- 认知改善与抑郁症状或基线特征无相关性(R2≤0.02)。
- 预设次要抑郁终点MADRS趋势获益始于第6周,第10周最大(2.7分,Cohen's d 0.43,p=0.05)。
- PGI-S评分趋势获益也在第10周最大(p=0.12)。
- emestedastat组10%出现轻度至中度转氨酶升高(8例中7例≤正常2倍,1例停药),安慰剂组1%。
关键数值与推荐
- 主要终点为第6周认知(注意/工作记忆复合评分),采用混合模型重复测量分析,认知损害和MADRS用单侧检验,其他用双侧检验,未校正多重比较。
- 抑郁终点包括MADRS和PGI-S;效应量用Cohen's d表示。
临床怎么用
- 对于持续抑郁伴认知损害的重性抑郁障碍患者,emestedastat 10 mg未显示认知改善获益,不应以改善认知为目的使用。
- emestedastat的潜在抗抑郁活性仅为趋势性发现,需进一步研究验证,目前不能作为临床推荐。
- 使用emestedastat时需监测转氨酶,试验中10%出现轻度至中度升高。
局限性
- 未对多重比较进行校正。
- 认知和抑郁的部分检验为单侧检验。
- 主要认知终点未达统计学显著性,抑郁获益仅为趋势性(p=0.05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most antidepressants do not independently treat impaired cognition associated with major depressive disorder (MDD). Elevated brain cortisol levels are associated with both MDD and cognitive impairment. Emestedastat is a brain-penetrant, intracellular cortisol synthesis inhibitor. AIMS: The XanaCIDD trial aimed to determine whether emestedastat 10 mg could improve both cognitive impairment and depression in a population with persistent MDD and cognitive impairment. METHOD: Participants had a diagnosis of MDD, with persistent depression (Hamilton Rating Scale for Depression-17 ≥17) and cognitive impairment (coding test ≤0.5 s.d. of normal). Randomised treatment (1:1) was continued for 6 weeks (week 6), with 4 weeks' blinded follow-up (week 10). The primary end-point was cognition (composite of attention/working memory) at week 6. Depression end-points included Montgomery-Åsberg Depression Rating Scale (MADRS) and Patient Global Impression of Severity (PGI-S). Analyses used a mixed model for repeated measures (cognitive impairment and MADRS one-sided tests, others two-sided) and Cohen's d effect size. No adjustments were made for multiple comparisons. RESULTS: A total of 165 participants were enrolled and treated: 134 (81%) were on background antidepressants, 62% were female, mean prior number of MDD episodes was 10 and mean coding z-score was -1.47. There was no benefit on the primary cognitive end-point at week 6 (p = 0.17 favouring placebo), with the cognitive composite improving markedly in both groups without correlation to depressive symptoms or baseline characteristics (R2 ≤ 0.02). The trend towards benefit on the prespecified secondary depression end-point, MADRS, began at week 6 and was maximal at week 10 (2.7 points, Cohen's d 0.43, p = 0.05). A trend towards potential emestedastat benefit in PGI-S scores was also maximal at week 10 (p = 0.12). Mild-moderate transaminase elevations were seen in 10% of emestedastat participants (≤2 times normal in 7 of 8 cases, 1 discontinuation) versus 1% of the placebo group. CONCLUSIONS: There was no benefit of emestedastat on the primary end-point of cognitive impairment and a large placebo effect, without correlation of cognitive impairment to depression changes or baseline characteristics. Trends towards potential antidepressant activity suggest that emestedastat may be a novel antidepressant worthy of further investigation.
引用
- Taylor JD, Rolan PE, Jaros MJ, et al. A Phase 2 randomised, double-blind, placebo-controlled trial of emestedastat in patients with major depressive disorder and cognitive impairment. Br J Psychiatry. 2026. PMID: 42464916. doi:10.1192/bjp.2026.10689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。